JPWO2020128049A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020128049A5 JPWO2020128049A5 JP2021535950A JP2021535950A JPWO2020128049A5 JP WO2020128049 A5 JPWO2020128049 A5 JP WO2020128049A5 JP 2021535950 A JP2021535950 A JP 2021535950A JP 2021535950 A JP2021535950 A JP 2021535950A JP WO2020128049 A5 JPWO2020128049 A5 JP WO2020128049A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- heavy chain
- bispecific antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 8
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 5
- 208000009292 Hemophilia A Diseases 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 229950006925 emicizumab Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 238000005734 heterodimerization reaction Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820977.5A GB201820977D0 (en) | 2018-12-21 | 2018-12-21 | Fixaxfx bispecific antibody with commomn light chain |
| GB1820977.5 | 2018-12-21 | ||
| GBGB1906816.2A GB201906816D0 (en) | 2019-05-15 | 2019-05-15 | FIXaxFX bispecific antibody with common light chain |
| GB1906816.2 | 2019-05-15 | ||
| GBGB1908190.0A GB201908190D0 (en) | 2019-06-07 | 2019-06-07 | Fixaxfx bispecific antibody with common light chain |
| GB1908190.0 | 2019-06-07 | ||
| PCT/EP2019/086808 WO2020128049A1 (en) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecific antibody with common light chain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515770A JP2022515770A (ja) | 2022-02-22 |
| JPWO2020128049A5 true JPWO2020128049A5 (enrdf_load_stackoverflow) | 2022-12-28 |
| JP7530362B2 JP7530362B2 (ja) | 2024-08-07 |
Family
ID=69167786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535950A Active JP7530362B2 (ja) | 2018-12-21 | 2019-12-20 | 共通の軽鎖を有するＦＩＸａ×ＦＸ二重特異性抗体 |
Country Status (18)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| CA3123177A1 (en) | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
| CN115728433B (zh) * | 2021-08-27 | 2024-11-15 | 联邦生物科技(珠海横琴)有限公司 | IgG4型单克隆抗体电荷异质性的离子交换色谱检测方法 |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| EP4473008A2 (en) * | 2022-01-31 | 2024-12-11 | The Children's Hospital Of Philadelphia | Compositions and methods for treating factor ix deficiency |
| KR102749341B1 (ko) | 2022-07-08 | 2025-01-06 | 노보 노르디스크 에이/에스 | FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물 |
| GB202319967D0 (en) | 2023-12-22 | 2024-02-07 | Epsilogen Ltd | Heteromultimeric proteins |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| US20080075712A1 (en) | 2003-10-14 | 2008-03-27 | Kunihiro Hattori | Double Specific Antibodies Substituting For Functional Proteins |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| CA2603264C (en) | 2005-04-08 | 2017-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| WO2007003421A2 (en) | 2005-07-05 | 2007-01-11 | Glaxo Group Limited | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof |
| AU2007229698B9 (en) | 2006-03-24 | 2012-11-08 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| CA2650131A1 (en) * | 2006-04-14 | 2007-10-25 | Amgen Inc. | Agonist erythropoietin receptor antibodies |
| KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| WO2011078332A1 (ja) * | 2009-12-25 | 2011-06-30 | 中外製薬株式会社 | ポリペプチド多量体を精製するためのポリペプチドの改変方法 |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| EP2644698B1 (en) * | 2010-11-17 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| CA2871068C (en) | 2012-04-20 | 2022-06-14 | Merus B.V. | Methods and means for the production of ig-like molecules |
| EP2906599B1 (en) | 2012-10-12 | 2019-07-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| JP6618893B2 (ja) * | 2013-04-29 | 2019-12-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｆｃ受容体結合が変更された非対称抗体および使用方法 |
| CA2929671A1 (en) | 2013-11-04 | 2015-05-07 | The Regents Of The University Of California | Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation |
| DK3089994T3 (da) | 2013-12-30 | 2022-07-04 | Epimab Biotherapeutics Inc | Fabs-in-tandem-immunglobulin og anvendelser deraf |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| AU2016248817A1 (en) | 2015-04-17 | 2017-08-17 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| US20180179274A1 (en) * | 2015-06-26 | 2018-06-28 | Institute For Research In Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| WO2017072310A1 (en) | 2015-10-30 | 2017-05-04 | Medimmune Limited | Prevention of n-terminal truncation in igg light chains |
| EP3395835B1 (en) | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| WO2017132827A1 (en) * | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| KR102185867B1 (ko) | 2016-02-06 | 2020-12-02 | 에피맙 바이오테라퓨틱스 인코포레이티드 | Fabs-인-탠덤 면역글로불린 및 이의 용도 |
| BR112018073660A2 (pt) | 2016-05-16 | 2019-02-19 | Baxalta Incorporated | anticorpos anti-fator ix pádua |
| WO2018021450A1 (ja) | 2016-07-29 | 2018-02-01 | 中外製薬株式会社 | 増強されたｆｖｉｉｉ補因子機能代替活性を有する二重特異性抗体 |
| EP3509637B1 (en) | 2016-09-06 | 2024-11-27 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| MA46893A (fr) | 2016-11-23 | 2019-10-02 | Bioverativ Therapeutics Inc | Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation |
| MY204354A (en) | 2017-02-01 | 2024-08-24 | Novo Nordisk As | Procoagulant antibodies |
| WO2018145125A1 (en) | 2017-02-06 | 2018-08-09 | Applied Stemcell, Inc. | Coagulation factor viii mimetic protein and uses thereof |
| IL319308A (en) * | 2017-04-26 | 2025-04-01 | Eureka Therapeutics Inc ׂ A Delaware Corp | Structures that specifically recognize glypican 3 and their uses |
| WO2018209265A1 (en) | 2017-05-11 | 2018-11-15 | Atreca, Inc. | Anti-malarial antibodies that bind circumsporozoite protein |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| CN118994408A (zh) | 2017-09-29 | 2024-11-22 | 中外制药株式会社 | 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂 |
| JP2021502984A (ja) | 2017-11-15 | 2021-02-04 | ノヴォ ノルディスク アー／エス | Ｆｘ活性化を促進する第ｘ因子結合剤 |
| CA3123177A1 (en) * | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
-
2019
- 2019-12-20 CA CA3123177A patent/CA3123177A1/en active Pending
- 2019-12-20 RS RS20220069A patent/RS62848B1/sr unknown
- 2019-12-20 CN CN201980091786.3A patent/CN113453757B/zh active Active
- 2019-12-20 KR KR1020217022770A patent/KR20210118085A/ko active Pending
- 2019-12-20 HU HUE19836806A patent/HUE057634T2/hu unknown
- 2019-12-20 BR BR112021012065A patent/BR112021012065A2/pt not_active Application Discontinuation
- 2019-12-20 PT PT198368060T patent/PT3723858T/pt unknown
- 2019-12-20 SI SI201930150T patent/SI3723858T1/sl unknown
- 2019-12-20 US US16/722,452 patent/US10815308B2/en active Active
- 2019-12-20 DK DK19836806.0T patent/DK3723858T3/da active
- 2019-12-20 LT LTEPPCT/EP2019/086808T patent/LT3723858T/lt unknown
- 2019-12-20 EP EP19836806.0A patent/EP3723858B1/en active Active
- 2019-12-20 HR HRP20220088TT patent/HRP20220088T1/hr unknown
- 2019-12-20 TW TW108146911A patent/TWI772724B/zh active
- 2019-12-20 JP JP2021535950A patent/JP7530362B2/ja active Active
- 2019-12-20 ES ES19836806T patent/ES2901683T3/es active Active
- 2019-12-20 EP EP21204339.2A patent/EP4015538A1/en active Pending
- 2019-12-20 WO PCT/EP2019/086808 patent/WO2020128049A1/en unknown
- 2019-12-20 PL PL19836806T patent/PL3723858T3/pl unknown
- 2019-12-20 US US17/311,595 patent/US20220064327A1/en not_active Abandoned
-
2020
- 2020-10-06 US US17/063,905 patent/US11976135B2/en active Active